CA2537978C - Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase - Google Patents
Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase Download PDFInfo
- Publication number
- CA2537978C CA2537978C CA2537978A CA2537978A CA2537978C CA 2537978 C CA2537978 C CA 2537978C CA 2537978 A CA2537978 A CA 2537978A CA 2537978 A CA2537978 A CA 2537978A CA 2537978 C CA2537978 C CA 2537978C
- Authority
- CA
- Canada
- Prior art keywords
- chloro
- cyano
- anilino
- compound
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés représentés par la formule (1), présentant la structure (I), dans laquelle R¿1?, R¿2? et R¿3? désignent des éléments décrits dans la partie descriptive de la présente demande. Ces composés agissent comme des agents anticancéreux et inhibent HER-2 et EGFR.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66227303A | 2003-09-15 | 2003-09-15 | |
US10/662,273 | 2003-09-15 | ||
PCT/US2003/032612 WO2005034955A1 (fr) | 2003-09-15 | 2003-10-15 | Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2537978A1 CA2537978A1 (fr) | 2005-04-21 |
CA2537978C true CA2537978C (fr) | 2011-08-02 |
Family
ID=34435322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2537978A Expired - Lifetime CA2537978C (fr) | 2003-09-15 | 2003-10-15 | Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1670473A1 (fr) |
AU (1) | AU2003304497B2 (fr) |
BR (1) | BR0318503A (fr) |
CA (1) | CA2537978C (fr) |
MX (1) | MXPA06002846A (fr) |
UA (1) | UA85394C2 (fr) |
WO (1) | WO2005034955A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
KR20080016671A (ko) * | 2005-05-25 | 2008-02-21 | 와이어쓰 | 치환된 3-시아노퀴놀린 및 그것의 중간체를 합성하는 방법 |
RU2451524C2 (ru) | 2005-11-04 | 2012-05-27 | Вайет | Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272 |
CA2649146A1 (fr) * | 2006-04-14 | 2007-10-25 | Astrazeneca Ab | 4-anilinoquinoleine-3-carboxamides en tant qu'inhibiteurs de la csf-ir kinase |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP2310011B1 (fr) | 2008-06-17 | 2013-07-24 | Wyeth LLC | Combinaisons antinéoplasiques contenant du hki-272 et de la vinorelbine |
KR101434009B1 (ko) | 2008-08-04 | 2014-08-25 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
CN101723854A (zh) | 2008-10-24 | 2010-06-09 | 上海特化医药科技有限公司 | 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体 |
PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
GB0922302D0 (en) * | 2009-12-22 | 2010-02-03 | Imp Innovations Ltd | Compounds |
CN102146084B (zh) * | 2010-02-04 | 2014-05-07 | 江苏恒瑞医药股份有限公司 | 3-氰基-6-氨基喹啉类衍生物、其制备方法及其在医药上的应用 |
EP2688565A1 (fr) | 2011-03-23 | 2014-01-29 | Semorex Technologies Ltd. | Traitement des troubles de la prolifération |
CN102718679B (zh) * | 2011-03-30 | 2016-06-08 | 北京万全阳光医药科技有限公司 | 一种诺那替尼关键中间体的制备方法 |
CN102731395B (zh) * | 2011-04-15 | 2015-02-04 | 中国科学院上海药物研究所 | 抗肿瘤药物来那替尼的中间体及其制备与应用 |
RS55704B1 (sr) | 2012-01-17 | 2017-07-31 | Astellas Pharma Inc | Jedinjenje pirazin karboksamida |
CN104926669A (zh) * | 2014-03-18 | 2015-09-23 | 江苏豪森医药集团连云港宏创医药有限公司 | 反式-4-二甲基胺基巴豆酸盐酸盐的制备方法 |
EP3677583A4 (fr) * | 2017-09-01 | 2021-07-21 | Shanghai Pharmaceuticals Holding Co., Ltd. | Composé hétérocyclique azoté, procédé de préparation, intermédiaire, composition et application |
CN110357854A (zh) * | 2018-03-26 | 2019-10-22 | 江苏创诺制药有限公司 | 一种来那替尼的制备方法 |
CN111848581B (zh) * | 2020-08-19 | 2021-08-10 | 昆明学院 | 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法 |
CN111995618B (zh) * | 2020-09-02 | 2021-06-11 | 重庆医科大学 | 一种来那替尼杂质g的制备方法 |
CN111943933B (zh) * | 2020-09-02 | 2021-05-28 | 重庆医科大学 | 一种来那替尼杂质d的制备方法 |
CN114920695B (zh) * | 2022-06-29 | 2023-06-20 | 深圳大学总医院 | 一种喹唑啉衍生物及其制备方法、药物组合物和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
DE60221886D1 (de) * | 2001-11-27 | 2007-09-27 | Wyeth Corp | 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen |
-
2003
- 2003-10-15 AU AU2003304497A patent/AU2003304497B2/en not_active Ceased
- 2003-10-15 EP EP03818857A patent/EP1670473A1/fr not_active Withdrawn
- 2003-10-15 MX MXPA06002846A patent/MXPA06002846A/es active IP Right Grant
- 2003-10-15 CA CA2537978A patent/CA2537978C/fr not_active Expired - Lifetime
- 2003-10-15 UA UAA200604144A patent/UA85394C2/ru unknown
- 2003-10-15 WO PCT/US2003/032612 patent/WO2005034955A1/fr active Application Filing
- 2003-10-15 BR BRPI0318503-6A patent/BR0318503A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR0318503A (pt) | 2006-09-12 |
UA85394C2 (ru) | 2009-01-26 |
EP1670473A1 (fr) | 2006-06-21 |
CA2537978A1 (fr) | 2005-04-21 |
AU2003304497A1 (en) | 2005-04-27 |
WO2005034955A1 (fr) | 2005-04-21 |
MXPA06002846A (es) | 2006-06-14 |
AU2003304497B2 (en) | 2010-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7399865B2 (en) | Protein tyrosine kinase enzyme inhibitors | |
CA2537978C (fr) | Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase | |
AU763669B2 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
EP1448531B1 (fr) | 3-cyanoquinolines en tant qu'inhibiteurs de kinases egf-r et her2 | |
US6002008A (en) | Substituted 3-cyano quinolines | |
DE69733008T2 (de) | Chinazolinderivate als antitumormittel | |
US6288082B1 (en) | Substituted 3-cyanoquinolines | |
US7304059B2 (en) | Substituted quinazolin-4-ylamine analogues | |
KR101540421B1 (ko) | 혈관신생 저해제로서 스피로 치환된 화합물 | |
AU750906B2 (en) | Substituted 3-cyano quinolines | |
EP2125776A1 (fr) | Composés substitués de spiro comme inhibiteurs d'angiogenèse | |
WO2006127203A2 (fr) | Procedes de synthese de derives de 6-alkylaminoquinoline | |
JP2004517059A (ja) | 抗腫瘍剤用の4−置換キノリン類 | |
BRPI0318503B1 (pt) | Quinolinas substituídas e composição farmacêutica compreendendo as mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |